Released Oct 29, 2020, before the open
10-Q filed Oct 29, 2020, 29 days after period end · 0001558370-20-011974
Q3 2020 · 10-Q
Revenue$10.79M$10.79M −24.3% vs Q3 2019−1.6% vs Q2 2020
Net Income-$4.44M-$4.44M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.14-$0.14 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$2,582,000N/M
Operating Cash Flowderived-$3,604,000N/M
Free Cash Flowderived-$3,706,000N/M
Margins · derived
Operating margin-23.9%−13.1 pt vs Q3 2019
Net margin-41.1%−16.1 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $10.79M | $14.25M | $663.00K | $7.53M |
| Net Income | -$4.44M | -$3.56M | -$5.32M | -$11.44M |
| EPS Diluted | -$0.14 | -$0.24 | -$0.40 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR